Steven D Wittlin

Title: The Innovative Contributions of Steven D. Wittlin

Introduction

Steven D. Wittlin is a notable inventor based in Rochester, NY (US). He has made significant contributions to the field of diabetes management through his innovative patent. His work focuses on improving the estimation of blood glucose excursions in diabetic patients, which is crucial for effective treatment and management of the condition.

Latest Patents

Wittlin holds a patent for a method of estimation of blood glucose excursions in diabetic patients using the 1,5-anhydroglucitol (1,5-AG) assay. This invention provides a method for measuring blood glucose excursions in general, and postprandial hyperglycemia in diabetic patients in particular. The 1,5-AG levels and percent changes in these levels over a short period are indicative of differing post-meal glucose levels in moderately-controlled diabetic patients with similar A1C levels. This assay is particularly useful for identifying diabetic patients who may be at risk for cardiovascular complications that would not be identifiable by A1C levels alone. Furthermore, the ratios of A1C divided by 1,5-AG in each patient serve as superior indicators compared to 1,5-AG levels alone.

Career Highlights

Throughout his career, Wittlin has worked with prominent companies such as Nippon Kayaku and Toyota Tsusho America, Inc. His experience in these organizations has contributed to his expertise in the field of diabetes research and innovation.

Collaborations

Wittlin has collaborated with esteemed professionals in the field, including John Bernard Buse and Kathleen Dungan. These collaborations have further enhanced his research and development efforts in diabetes management.

Conclusion

Steven D. Wittlin's innovative work in diabetes management through his patent on the 1,5-AG assay demonstrates his commitment to improving patient care. His contributions are vital for advancing the understanding and treatment of diabetes, ultimately benefiting many patients.